Antineoplastic Effect of Sulfanilamide Hybridized with Ciprofloxacin "In Vitro Study"

Abstract

Khalida K Abbas Al-Kelaby, Noor H. Naser, Azhar Jasim AL-Kaabi, Mohamed Hassan Mohammed.

Many efforts have focused on the therapeutic approach of cancer for a long time by studying cytotoxic activities of different compounds including synthetic, semi synthetic and plant constituents. This work involved synthesis of 1-cyclopropyl-6-fluoro-4-oxo-7-4-2-oxo-2-(4-sulfamoylphenylamino) ethyl piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid compound named as (CSA) prepared by hybridization of sulfanilamide with ciprofloxacin was applied against HCT116 colorectal adenocarcinoma cell line. This study was planned to evaluate cytotoxicity of CSA by thiazolyl blue tetrazolium bromide (MTT) cytotoxicity test by using HCT116 cell line aiming to introduce an alternative therapeutic compound as compared with standard chemotherapeutic drugs such as doxorubicin (DOX) and 5-Fluorouracil (5-FU), by the assessment of half maximal inhibitory concentration (IC50). Results showed that CSA compound was effectively and significantly inhibit HCT116 cells proliferation (p<0.0001) at different concentrations involved 1, 10, 100, 500 and 1000 μg/ml, with IC50 of 182.4 μg/ml. Values of DOX and 5-FU IC50 were 58.94μg/ml and 36.73μg/ml respectively. We concluded that CSA compound may have anticancer effect against HCT116 colorectal adenocarcinoma cell line, and future in vivo study to confirm this result is strongly recommended.